Intrinsiqq
DBV Technologies S.A. logo

DBV Technologies S.A. Quality Score

DBVT

⊜ Compare
Quality10

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-16.3x

Negative earnings, no valuation support

Cash Flow Multiple
0/100
-16.3x

Negative FCF, no valuation support

Revenue Growth
0/100
-6.3%

Below 2%, essentially flat

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
0/100
1065.7%

Heavy dilution above 5%

Margin Trend
0/100
-3582.1pp

Contracted >2pp, margin pressure

Capital Structure
100/100
-$158M

Net cash position, no leverage concern

2022
$209M
$3.00M
2023
$141M
$6.00M
2024
$32.0M
$7.00M
2025
$194M
$7.00M
TTM
$166M
$8.00M
CashDebt
Return on Capital
0/100
-92.3%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

DBV Technologies (DBVT) quality: score, margins and returns

DBV Technologies (DBVT) scores 10/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 6 metrics each scored 0 to 100, on -5,577.0% operating margins and -92.3% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is DBV Technologies (DBVT) a high-quality business?+

DBV Technologies scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -5,577.0% operating margin and a -92.3% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does DBV Technologies's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from DBVT's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where DBV Technologies scores well and where it falls behind.

What is DBV Technologies's return on invested capital (ROIC)?+

DBV Technologies earns about -92.3% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to DBVT's margins and growth on this scorecard to judge durability.

How profitable is DBV Technologies?+

DBV Technologies runs an operating margin of about -5,577.0% and a net margin of about -5,547.3%. Revenue has grown at roughly -13.0% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 26 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 29 Oct 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with DBVT

CompareIntrinsic value
ALGSAligos Therapeutics Inc.
$5.02+5.68%10
DYAIDyadic International Inc.
$0.37+1.86%36
CRISCuris Inc.
$1.11+56.34%25
OCGNOcugen Inc.
$0.88+17.45%40
PRMEPrime Medicine Inc.
$4.97+9.23%0
HUMAHumacyte, Inc.
$0.45+2.04%10
TSHATaysha Gene Therapies Inc.
$4.36+6.60%40
OTLKOutlook Therapeutics Inc.
$0.46+0.46%10

Held by ETFs

DBVT is in 2 US ETFs. The largest of them, with DBVT's weight in each:

Spot a number that looks wrong? Check it in DBVT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing DBVT

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.